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Abstract
Background: Immune responses to Mycobacterium tuberculosis antigens could serve as surrogate
markers of treatment response.
Methods:  Using the T-SPOT.TB  assay and frozen peripheral blood mononuclear cells, we
enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB
patients receiving directly observed treatment. T cell responses (measured as "spot forming cells"
or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment.
Results: 58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-
10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at
baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of
24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted
to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks
of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6,
CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20),
and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were
higher than those without cavitary disease (IRR 2.08, p = 0.034).
Conclusion: IFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.TB assay, may be
directly related to bacterial load in patients undergoing treatment for pulmonary TB. However,
high inter-subject variability in quantitative results coupled with failure of reversion to negative of
qualitative results in most subjects at treatment completion may limit the utility of this assay as a
surrogate marker for treatment efficacy.
Background
Progress in understanding the genome of Mycobacterium
tuberculosis  and human host responses has led to the
rational development of diagnostic tests for tuberculosis
(TB).[1] Early secretory antigenic target-6 (ESAT-6) and
culture filtrate protein 10 (CFP-10) are secreted antigens
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encoded by region of difference-1 (RD1) of M. tuberculosis.
These antigens elicit IFN-γ secretion by peptide-specific T
cells.[1,2] Diagnostic tests have been developed to meas-
ure response T cell responses to these antigens.[3] T-
SPOT.TB (Oxford Immunotec Ltd, Abingdon, Oxon, UK)
is an ex vivo enzyme-linked immunospot (ELISPOT)
assay that uses overlapping peptide panels to stimulate
IFN-γ secretion by ESAT-6 and CFP-10-specific T cells.
Among individuals with active TB, the T-SPOT.TB test and
similar ELISPOT tests have reported sensitivities of 83–
97%. [1,4-10] In addition, compared with the tuberculin
skin test, the T-SPOT.TB and similar ELISPOT tests have
been shown to correlate more closely with extent of M.
tuberculosis exposure in contacts of TB patients. [11-13]
However, the role of T-SPOT.TB in monitoring response
to TB treatment is less well-established. A blood test that
correlated well with severity of disease or treatment
response might be useful as a surrogate marker in clinical
trials of new TB treatments, to predict TB treatment failure
and/or relapse, and to monitor treatment response in con-
ditions such as extrapulmonary TB or childhood TB in
which sputum is uninformative or not readily obtainable.
In order to assess the potential utility of T-SPOT.TB for
monitoring treatment efficacy, we evaluated the relation-
ship between frequency of antigen-specific IFNγ-secreting
T cells and treatment response in patients with pulmonary
TB receiving directly observed therapy (DOT) in the con-
text of a phase II TB treatment study. We also evaluated
the relationship between SFC counts and markers of TB
disease severity at baseline.
Methods
Setting and design
We performed a longitudinal cohort study of a diagnostic
test, nested in a Phase II, single-center, double-blind TB
treatment trial in Rio de Janeiro, Brazil [14]. The aims of
the treatment trial were to evaluate and compare the anti-
microbial activity of two daily TB treatment regimens
administered during the first 8 weeks of treatment in
patients with pulmonary TB. The control treatment arm
was comprised of isoniazid, rifampin, pyrazinamide, and
ethambutol (HRZE), and the experimental arm was com-
prised of isoniazid, rifampin, pyrazinamide, and moxi-
floxacin (HRZM). All drugs were given by directly
observed therapy (DOT) five days per week. For the treat-
ment trial, the primary endpoint was sputum culture sta-
tus (positive or negative for M. tuberculosis) at completion
of 8 weeks of treatment. All participants in the treatment
trial were eligible for participation in the T-SPOT.TB diag-
nostic study. Blood for the T-SPOT.TB assay was collected
just prior to initiation of TB therapy (week 0, baseline)
and at 16 and 24 weeks of treatment. The treatment and
diagnostic studies were approved by the ethics review
boards of the Johns Hopkins University School of Medi-
cine and the Hospital Universitario Clementino Fraga
Filho in Rio de Janeiro, Brazil.
Participants
Subjects were adults with smear positive, culture-con-
firmed pulmonary TB that was susceptible to all of the
treatment drugs. Additional inclusion criteria were docu-
mented HIV status (positive or negative), no history of
prior TB treatment, and Karnofsky performance status
score 70 or greater. Subjects were excluded if they had
only extrapulmonary TB, were being treated with HIV-1
protease inhibitors, were pregnant or breastfeeding, had
AST > 3 times normal, total bilirubin > 2.5 times normal,
creatinine > 2 times normal, hemoglobin < 7.0 g/dL,
potassium < 3.5 mEq/L, or platelet count < 50,000/mm3.
Upon initiation of the T-SPOT.TB substudy, all subjects
enrolled into the parent treatment trial were co-enrolled
in the TSPOT-TB study until completion of the treatment
trial.
Study evaluations
Enumeration of RD1-specific T cells
Whole venous blood was drawn into 8 ml CPT tubes (Bec-
ton Dickinson, Franklin Lakes, NJ) at weeks 0, 16, and 24
of TB treatment. Peripheral blood mononuclear cells
(PBMC) were isolated by centrifugation, washed twice,
resuspended in Recovery™ cell culture freezing media
(Gibco, Invitrogen Corp., Carlsbad, CA), and frozen in
liquid nitrogen until T-SPOT.TB testing. Just prior to test-
ing, samples were thawed; twice, AIM V medium (Gibco,
Invitrogen) was added and the samples were centrifuged.
The PBMC pellet was resuspended in AIM V medium, and
T-SPOT.TB  assays using 8-well strips were performed
according to the manufacturer's instructions.[15] For an
individual study subject, all frozen samples were thawed
and tested at one time, such that the final specimen (the
24 week specimen) was frozen for a minimum of 30 days.
The assay included nil control, ESAT-6-derived peptide
(Panel A), CFP-10-derived peptide (Panel B), and positive
control wells. SFCs were enumerated on-site using a hand-
held magnifying glass. As per the manufacturer's instruc-
tions, for ESAT-6 and for CFP-10, a test was scored as qual-
itatively reactive if either: (1) for nil control of 0–5 SFCs,
the antigen well SFC count minus the nil control SFC
count was ≥ 6; or (2) for nil control of > 5 SFCs, the anti-
gen SFC count was ≥ 2 times the nil control SFC count.
Overall, a T-SPOT.TB test was considered reactive if either
ESAT-6 or CFP-10 was reactive, or considered nonreactive
if both ESAT-6 and CFP-10 were nonreactive. The number
of ESAT-6-specific SFCs was calculated by subtracting the
nil control SFC count from the Panel A SFC count; the
number of CFP-10-specific SFCs was calculated by sub-
tracting the nil control SFC count from the Panel B SFC
count. The resulting ESAT-6 and CFP-10 values were sum-BMC Infectious Diseases 2009, 9:23 http://www.biomedcentral.com/1471-2334/9/23
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mated to give the total RD1 SFC count. Those wells with
too-numerous-to-count SFCs were assigned a value of 400
which approximates the upper limit of quantification. The
technologist performing the TSPOT-TB  assays was not
aware of patients' clinical or microbiological status.
Mycobacterial culture
For each subject, sputa were collected weekly through
week 8, then monthly. Specimens were digested and
decontaminated using the Nalc-NaOH method, and
resuspended in 2.0 mL of phosphate buffer. Two 0.2 ml
portions of resuspended sediment were plated onto
Löwenstein-Jensen medium and incubated at 37°C for up
to 8 weeks. For positive cultures, species identification was
performed using conventional biochemical methods.
Statistical analyses
To determine whether or not overall SFC counts changed
over time with TB treatment, we compiled T-SPOT.TB
results from baseline, 16 weeks of treatment, and 24
weeks of treatment. To compare SFC counts between
those with positive and negative sputum cultures at treat-
ment week 8 and to compare SFC counts between those
with and without cavitary disease, we performed a longi-
tudinal data analysis. To model the dependency resulting
from repeated measures, and given that SFC counts repre-
sented overdispersed count data, the data were analyzed
using a marginal model with negative binomial approach
with generalized estimating equation methods
(GEE).[16] We chose an independent correlation struc-
ture with robust standard errors for the GEE models, as
quantitative statistical comparisons of fit showed that this
correlation structure provided the best fit. Negative bino-
mial regression models were used to analyze differences
in SFC counts between groups at treatment week 24. Sign-
rank tests were used to compare SFC counts before and
after treatment. Two-sided alpha levels of 0.05 were used
to determine statistical significance in all analyses. Statis-
tical analyses were performed using STATA statistical soft-
ware (StataCorp, College Station, Texas).
Results
Demographic and clinical characteristics of study 
participants
During the T-SPOT.TB study period, 73 individuals were
enrolled in the TB treatment trial. Among these 73 sub-
jects, 11 had no baseline T-SPOT.TB result and 4 had only
a baseline T-SPOT.TB  result; these 15 subjects were
excluded from the analysis. The remaining 58 patients
had at least two blood samples collected, including a
baseline sample, and were included in the analysis.
Table 1 shows the baseline characteristics of the study
population. Only one subject was HIV-infected (CD4 426
cells/mm3); ESAT-6 and CFP-10 spot forming counts for
this patient were 14 and 99 at week 0, 4 and 77 at week
16, and 8 and 63 at week 24, resulting in a qualitatively
reactive test at all time-points. Sensitivity of the T-
SPOT.TB test, as measured by baseline reactivity of frozen
samples, was 72.4% (95% CI 59–83%).
Association between SFC counts and severity of TB disease 
at baseline
To determine whether or not SFC counts were higher
among those with more severe TB, we evaluated the asso-
ciation between SFC counts and two markers of disease
severity at baseline – cavitary lung disease and low body
mass index (BMI). For ESAT-6, those with cavitary disease
had, on average, 2.08 times higher SFC counts than those
without cavitary disease (95% confidence interval for the
incidence rate ratio [IRR] 1.06 to 4.10, p = 0.034), but
CFP-10 SFC counts did not differ between the two groups
(p = 0.64). There was no association between baseline
BMI and either ESAT-6 or CFP-10 SFC counts (p = 0.48
and 0.48, respectively).
SFC counts over time during TB treatment
As shown in Figure 1, mean SFC counts declined over 24
weeks for ESAT-6, CFP-10, and summed RD1. Mean (SD)
ESAT-6 SFC declined by 22.2 (62.9) over 24 weeks (p =
0.01 by signrank test), but CFP-10 SFC declined, on aver-
age, by only 8.9 (41.2) over 24 weeks (p = 0.18).
Table 2 shows the percent of study subjects having a reac-
tive qualitative result for ESAT-6, CFP-10, and RD1 at the
three time-points. Using qualitative results, there were no
significant trends over time, and no differences between
percentages of subjects positive by ESAT-6 versus by CFP-
10 at any of the time-points. Of 42 individuals who had a
reactive baseline test, 40 were retested at week 24; of these
40, 4 (10%) had a non-reactive T-SPOT.TB test at week 24.
Table 1: Baseline characteristics of the study population.
Total (n = 58)
Characteristic
Mean age in years (SD) 33.4 (10.8)
Male (%) 36 (62.1)
Baseline weight in kg (SD) 55.7 (9.1)
Cavitary disease** (%) 41 (70.7)
Diabetes mellitus (%) 10 (17.2)
Assigned to HRZM treatment arm (%) 31 (54.4)
HIV-positive (%) 1 (1.7)†
*cavitary disease on baseline chest radiograph
† CD4 = 426 cells/mm3
SD, standard deviation
HRZE, combination treatment with 
isoniazid+rifampin+pyrazinamide+moxifloxacin.BMC Infectious Diseases 2009, 9:23 http://www.biomedcentral.com/1471-2334/9/23
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SFC counts among patients who were sputum culture 
positive versus negative at completion of 8 weeks of TB 
treatment
Next, we compared SFC counts between individuals who
remained sputum culture positive at completion of 8
weeks of treatment and individuals who were sputum cul-
ture negative at completion of 8 weeks of treatment. Forty-
eight (82.8%) of 58 individuals were culture negative at 8
weeks, and 10 (17.2%) of 58 remained culture positive.
As shown in Figure 2, individual participant RD1 SFC
response profiles demonstrated large intersubject and
intrasubject variability. Mean SFC counts are shown in
Figure 3. Compared with subjects having negative culture
results, culture positive subjects had higher mean SFC
counts at all time points and for both ESAT-6 and CFP-10.
Mean ESAT-6 SFC count was on average 2.23 times higher
for the group that was culture positive at completion of 8
weeks of treatment than for the group that was culture
negative (IRR 95% CI 1.01 to 4.93, p = 0.048). The mean
CFP-10 SFC count was on average 1.51 times higher for
the culture positive group compared to the culture nega-
tive group, but this difference did not reach statistical sig-
nificance (IRR 95% CI 0.80 to 2.85, p = 0.20). The mean
RD1 SFC count was on average 1.83 times higher for the
culture positive group compared to the culture negative
group (IRR 95% CI 1.01 to 3.33, p = 0.047); the rate of
decline did not differ between the two groups (p = 0.54).
At completion of 24 weeks of therapy, the culture positive
group had ESAT-6 and CFP-10 counts that were 2.27 (IRR
95% CI 0.82 to 6.31) and 2.36 (IRR 95% CI 0.92 to 6.04)
times higher than the culture negative group, but neither
of these differences reached statistical significance.
Using qualitative results (Table 2), compared with culture
negative subjects, slightly higher percentages of culture
positive subjects had ESAT-6 or CFP-10 results classified
as reactive at weeks 0, 16, and 24, but differences were not
statistically significant.
Mean ESAT-6, CFP-10, and summed RD1 specific spot forming cells at weeks 0 (baseline), 16, and 24 for all study participants  (n = 58) Figure 1
Mean ESAT-6, CFP-10, and summed RD1 specific spot forming cells at weeks 0 (baseline), 16, and 24 for all 
study participants (n = 58). SFC, spot forming cells. Vertical bars represent standard deviations of the means.
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Discussion
There has been considerable debate about the immune
response to M. tuberculosis and correlates of bacterial con-
tainment in the human host. It has been postulated that
active TB infection is immunosuppressive and that treat-
ment of TB would lead to improved immune function and
an increase in antigen-specific IFN-γ production by T
cells.[17] Our data support an alternate hypothesis that
treatment leads to decreased antigen burden and, in turn,
diminished frequency of circulating antigen-specific T
cells. In this regard, our findings are consistent with those
of several prior studies using precommercial RD1-based
interferon gamma release ELISPOT assays. [1,4,18,19]
Specifically, Pathan et al. used an RD1-specific ELISPOT
assay to evaluate kinetics of T cell responses in 12 active
TB patients undergoing treatment.[1] They observed an
average 38% decrease in SFCs over a mean follow-up
period of 18.6 weeks. Aiken et al. showed that 55% of
treated pulmonary TB patients had negative ESAT-6/CFP-
10 ELISPOT tests one year after treatment initiation.[19]
Some studies using precommercial assays, however, have
demonstrated persistently high or positive RD1-specific
ELISPOT test results even after treatment; multiple techni-
cal or environmental factors may affect assay performance
characteristics.[20,21] One study using the commercially-
available T-SPOT.TB comparing patients early in their TB
treatment to patients late in their TB treatment showed
significantly higher positive T-SPOT.TB proportions in the
early-treatment group (83% vs. 17%).[22]
Our findings add strength to the hypothesis that SFC
counts directly reflect bacillary burden and, importantly,
used the commercially available T-SPOT.TB assay. Mean
ESAT-6 and summed RD1 SFC counts were statistically
significantly higher in the group with positive sputum cul-
tures at week 8 compared with the group having negative
sputum cultures at week 8. These differences were appar-
ent at baseline (time 0), and overall rates of decline in
RD1 SFC counts did not differ between groups. These data
suggest that higher SFC counts in those with positive spu-
tum culture results at week 8 resulted from higher pre-
treatment bacillary burdens of M. tuberculosis rather than
from a slower decline in SFC counts during treatment. In
addition, there was an association between ESAT-6 SFC
count and presence of lung cavitation – a manifestation of
TB disease usually characterized by high bacillary burden.
Additional studies of M. tuberculosis exposure, progression
from latent to active TB, and treatment of latent TB also
support the hypothesis that quantitative ELISPOT readout
reflects mycobacterial burden. Specifically, Hill et al.
found that, in individuals with positive ELISPOT
responses to ESAT-6 and CFP-10, quantitative ELISPOT
responses to PPD reflected the infectious load of M. tuber-
culosis as a result of recent exposure.[23] Richeldi et al.
reported a newborn child exposed to TB – ELISPOT results
turned positive at age 6 months, and were approximately
10-fold higher at age 24 months when the child devel-
oped overt TB disease.[24] In another case report, a rising
ELISPOT count heralded progression to active TB in a
patient with known latent TB.[25] With respect to treat-
ment of latent TB, Ewer et al. used an RD1-specific ELIS-
POT assay to evaluate kinetics of T cell responses in
individuals presumably recently infected with M. tubercu-
losis in the context of a point-source school-associated TB
outbreak.[26] Tuberculin skin test-positive students
treated with a three-month course of isoniazid and
rifampin had an average 68% decline per year in frequen-
cies of RD1 specific SFCs, but no change in frequencies of
these cells was observed in untreated individuals. Chee et
al. recently demonstrated that among individuals under-
going treatment for latent TB infection, treatment had a
significant effect on response to CFP-10 but not on
response to ESAT-6 as measured by the T-SPOT.TB
assay.[27]
While our results and those of others indicate that immu-
nologic responsiveness as measured by RD1-based inter-
feron gamma release ELISPOT assays is dynamic during
the course of M. tuberculosis disease and its treatment, our
results indicate that the test's utility in evaluating or pre-
dicting treatment response in individual patients appears
poor. Our results do not support this test's use as an early
surrogate marker for treatment response in clinical trials.
While overall SFC counts declined over the course of treat-
ment, individual patient response profiles (mapping SFC
counts over time) were highly variable in our study. Fur-
thermore, the proportion of patients with positive quali-
tative test results was not different between groups and
did not decline over time during treatment. Further stud-
ies evaluating this test in subgroups, such as HIV-seropos-
Table 2: Qualitative T-SPOT. TB results: % of subjects having a 
reactive test, stratified by stimulatory antigen and by culture 
results at completion of 8 weeks of TB treatment
Week 0 Week 16 Week 24
ESAT-6
All subjects 56.9 58.9 53.7
Culture positive 60.0 77.8 60.0
Culture negative 56.3 55.3 52.3
CFP-10
All subjects 55.2 58.9 59.3
Culture positive 60.0 77.8 60.0
Culture negative 54.2 55.3 59.1
RD1
All subjects 72.4 78.6 75.9
Culture positive 70.0 88.9 70.0
Culture negative 72.9 76.6 77.3BMC Infectious Diseases 2009, 9:23 http://www.biomedcentral.com/1471-2334/9/23
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Individual patient RD1 spot forming cell response profiles over 24 weeks of TB treatment for individuals having a negative spu- tum culture for M. tuberculosis at completion of 8 weeks of TB treatment (PANEL A, n = 48), and for individuals having a posi- tive sputum culture at completion of 8 weeks of TB treatment (PANEL B, n = 10) Figure 2
Individual patient RD1 spot forming cell response profiles over 24 weeks of TB treatment for individuals hav-
ing a negative sputum culture for M. tuberculosis at completion of 8 weeks of TB treatment (PANEL A, n = 48), 
and for individuals having a positive sputum culture at completion of 8 weeks of TB treatment (PANEL B, n = 
10). SFC, spot forming cells.
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itive patients or patients with solely extrapulmonary
disease, may help determine the utility of this test in these
special populations. The utility of an RD1-based inter-
feron gamma release ELISPOT assay in combination with
other immunologic tests to evaluate treatment response
also remains to be studied.
Our study has important limitations. First, we used frozen
cells for cost reasons. Freeze-thaw processes may have
diminished T cell reactivity, and this could account for the
lower-than-expected baseline sensitivity of the T-SPOT.TB
assay. We cannot exclude the possibility that frozen sam-
ples that were stored longest before testing (i.e., baseline
samples) could have been most affected by storage and
might have given spuriously low results; this could have
diminished our ability to detect a decrease in assay
responses with treatment. The effects of prolonged freez-
ing could be studied by dividing samples into two aliq-
uots, with one aliquot tested immediately and the other
frozen for later testing. Second, we compared T-SPOT.TB
to a surrogate marker–sputum culture status at comple-
tion of eight weeks of treatment–and not to the accepted
gold standard of durable TB cure without relapse after
treatment. This was done for efficiency and convenience
in our study but highlights the need and provides ration-
ale for additional studies of T-SPOT.TB responses during
long-term follow-up after completion of TB treatment. In
our study, only 10% of subjects with a reactive T-SPOT.TB
test at baseline had a nonreactive test at completion of 24
weeks of treatment. Aiken et al. showed that 55% of
treated pulmonary TB patients had negative ESAT-6/CFP-
10 ELISPOT tests one year after treatment initiation.[18] It
remains to be seen whether, after successful TB treatment,
SFC counts return to zero in a substantial majority of
patients at time points beyond one year. If this were the
case, the test might have utility in predicting or diagnosing
relapsed or recurrent TB disease. In our study, there were
no subjects with recognized TB treatment failure, and
therefore we were not able to evaluate T-SPOT.TB
responses in this important clinical scenario. We were also
Mean ESAT-6, CFP-10, and summed RD1 specific spot forming cells at weeks 0 (baseline), 16, and 24 for individuals having a  positive sputum culture for M. tuberculosis at completion of 8 weeks of TB treatment (SOLID BARS, n = 10), and for individuals  having a negative sputum culture at completion of 8 weeks of TB treatment (HATCHED BARS, n = 48) Figure 3
Mean ESAT-6, CFP-10, and summed RD1 specific spot forming cells at weeks 0 (baseline), 16, and 24 for indi-
viduals having a positive sputum culture for M. tuberculosis at completion of 8 weeks of TB treatment (SOLID 
BARS, n = 10), and for individuals having a negative sputum culture at completion of 8 weeks of TB treatment 
(HATCHED BARS, n = 48). SFC, spot forming cells. Vertical bars represent standard deviations of the means.
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unable to assess the kinetics of T cell responses early in
treatment, as funding limitations precluded the perform-
ance of an 8-week TSPOT-TB test. Of note, current manu-
facturer instructions in the U.S. FDA-approved T-SPOT.TB
assay classify those with spot counts of 5, 6, or 7 as bor-
derline and recommend retesting. Retesting was not done
for three individuals in our study who had spot counts of
5 at baseline, as manufacturer instructions at the time of
our study classified them as negative. Using the current
classification system, two of the three had positive results
upon completion of treatment while one had a negative
result, resulting in no substantive change in our overall
results or conclusions.
On the other hand, our study has several strengths. First,
the lab study was undertaken in a setting in which TB
treatment (under direct observation), sputum monitor-
ing, and subject follow-up were standardized and rigor-
ous. In addition, the T-SPOT.TB laboratory technologist
was not aware of patient status, thereby reducing potential
bias. Finally, for each study subject, all T-SPOT.TB speci-
mens were thawed and tested at the same time, thereby
reducing the impact of potential unrecognized time-
related differences in study procedures.
Conclusion
In conclusion, the correlation between ESAT-6 SFC counts
and cavitation on baseline chest radiograph, the decline
in SFC counts during treatment, and the observed differ-
ences in SFC counts between the group having positive 8-
week cultures versus the group having negative 8-week
cultures indicate that IFN-γ-producing RD1-specific T
cells, as measured by the T-SPOT.TB assay, may be directly
related to bacterial load in individuals undergoing treat-
ment for pulmonary TB. However, high inter-patient var-
iability in quantitative results as well as lack of reversion
to negative of qualitative results in patients at the time of
treatment completion, may limit the utility of this test as
an early surrogate marker for treatment response. Longitu-
dinal studies with long-term patient follow-up are war-
ranted in order to determine the utility of the T-SPOT.TB
test for detecting relapse after TB treatment.
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